Merck (MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, meeting the main goal of a late-stage clinical trial. However, patients receiving ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of one-year results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK ...
In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic ...
Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular ...
D’Amico concluded that remigromig is the first biologic with a novel mechanism of action that demonstrated a noninferior ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A University at Buffalo researcher who is a leading expert on retinopathy of prematurity (ROP) has published a study that could change the standard of care for the condition. ROP occurs in low ...
Intas Pharmaceuticals has launched RAZUMAB™, its biosimilar to Lucentis® (Ranibizumab). Intas is the first company globally to develop and launch a biosimilar version of Ranibizumab. RAZUMAB™ is ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of ranibizumab, having considered evidence on the nature of visual impairment caused by macular oedema ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results